About: Aplaviroc

An Entity of Type: chemical substance, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

Aplaviroc (INN, codenamed AK602 and GSK-873140) is a CCR5 entry inhibitor that belongs to a class of 2,5-diketopiperazines developed for the treatment of HIV infection. It was developed by GlaxoSmithKline. In October 2005, all studies of aplaviroc were discontinued due to liver toxicity concerns. Some authors have claimed that evidence of poor efficacy may have contributed to termination of the drug's development; the ASCENT study, one of the discontinued trials, showed aplaviroc to be under-effective in many patients even at high concentrations.

Property	Value
dbo:abstract	Aplaviroc (INN, codenamed AK602 and GSK-873140) is a CCR5 entry inhibitor that belongs to a class of 2,5-diketopiperazines developed for the treatment of HIV infection. It was developed by GlaxoSmithKline. In October 2005, all studies of aplaviroc were discontinued due to liver toxicity concerns. Some authors have claimed that evidence of poor efficacy may have contributed to termination of the drug's development; the ASCENT study, one of the discontinued trials, showed aplaviroc to be under-effective in many patients even at high concentrations. (en)
dbo:casNumber	461023-63-2 461443-59-4
dbo:chEMBL	1255794
dbo:fdaUniiCode	04D148Z3VR 98B425P30V
dbo:kegg	D06557
dbo:pubchem	3001322
dbo:thumbnail	wiki-commons:Special:FilePath/Aplaviroc_structure.svg?width=300
dbo:wikiPageID	15778762 (xsd:integer)
dbo:wikiPageLength	6501 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID	1095940228 (xsd:integer)
dbo:wikiPageWikiLink	dbr:Entry_inhibitor dbc:Entry_inhibitors dbc:Abandoned_drugs dbc:Spiro_compounds dbr:GlaxoSmithKline dbc:Hepatotoxins dbr:2,5-Diketopiperazine dbr:HIV dbc:Diphenyl_ethers dbc:Benzoic_acids dbc:Diketopiperazines dbr:International_Nonproprietary_Name dbr:Hepatotoxicity dbr:CCR5 dbr:CCR5_receptor_antagonist
dbp:atcPrefix	none (en)
dbp:c	33 (xsd:integer)
dbp:casNumber	461023 (xsd:integer) 461443 (xsd:integer)
dbp:chembl	1255794 (xsd:integer)
dbp:chemspiderid	2272720 (xsd:integer)
dbp:h	43 (xsd:integer)
dbp:index2Label	HCl (en)
dbp:iupacName	4 (xsd:integer)
dbp:iupharLigand	805 (xsd:integer)
dbp:kegg	D06557 (en)
dbp:legalStatus	Development terminated (en)
dbp:n	3 (xsd:integer)
dbp:o	6 (xsd:integer)
dbp:pubchem	3001322 (xsd:integer)
dbp:routesOfAdministration	Oral (en)
dbp:smiles	CCCCN1C[C@H][C@@H]O (en)
dbp:stdinchi	1 (xsd:integer)
dbp:stdinchikey	GWNOTCOIYUNTQP-FQLXRVMXSA-N (en)
dbp:unii	4 (xsd:integer) 98 (xsd:integer)
dbp:verifiedrevid	451871816 (xsd:integer)
dbp:width	300 (xsd:integer)
dbp:wikiPageUsesTemplate	dbt:Cite_journal dbt:Infobox_drug dbt:Reflist dbt:Short_description dbt:Cascite dbt:Chemspidercite dbt:Drugbankcite dbt:Fdacite dbt:Keggcite dbt:Stdinchicite dbt:Antiretroviral_drug dbt:Chemokine_receptor_modulators dbt:Antiinfective-drug-stub
dcterms:subject	dbc:Entry_inhibitors dbc:Abandoned_drugs dbc:Spiro_compounds dbc:Hepatotoxins dbc:Diphenyl_ethers dbc:Benzoic_acids dbc:Diketopiperazines
gold:hypernym	dbr:Inhibitor
rdf:type	owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 yago:WikicatMolecularFormulas yago:Abstraction100002137 yago:Agent114778436 yago:CausalAgent100007347 yago:Communication100033020 yago:Drug103247620 yago:Formula106816935 yago:Inhibitor114724436 yago:Matter100020827 yago:Message106598915 yago:MolecularFormula106817173 yago:PhysicalEntity100001930 dbo:Drug yago:Statement106722453 yago:Substance100020090 yago:WikicatEntryInhibitors umbel-rc:DrugProduct
rdfs:comment	Aplaviroc (INN, codenamed AK602 and GSK-873140) is a CCR5 entry inhibitor that belongs to a class of 2,5-diketopiperazines developed for the treatment of HIV infection. It was developed by GlaxoSmithKline. In October 2005, all studies of aplaviroc were discontinued due to liver toxicity concerns. Some authors have claimed that evidence of poor efficacy may have contributed to termination of the drug's development; the ASCENT study, one of the discontinued trials, showed aplaviroc to be under-effective in many patients even at high concentrations. (en)
rdfs:label	Aplaviroc (en)
owl:sameAs	freebase:Aplaviroc yago-res:Aplaviroc wikidata:Aplaviroc dbpedia-sh:Aplaviroc dbpedia-sr:Aplaviroc dbpedia-vi:Aplaviroc https://global.dbpedia.org/id/4RPtr
prov:wasDerivedFrom	wikipedia-en:Aplaviroc?oldid=1095940228&ns=0
foaf:depiction	wiki-commons:Special:FilePath/Aplaviroc_structure.svg
foaf:isPrimaryTopicOf	wikipedia-en:Aplaviroc
is dbo:wikiPageRedirects of	dbr:C33H43N3O6 dbr:Aplaviroc_hydrochloride dbr:GSK-873140 dbr:AK-602 dbr:AK602
is dbo:wikiPageWikiLink of	dbr:Entry_inhibitor dbr:2,5-Diketopiperazine dbr:C33H43N3O6 dbr:CCR5 dbr:CCR5_receptor_antagonist dbr:Aplaviroc_hydrochloride dbr:List_of_drugs:_An–Ap dbr:GSK-873140 dbr:AK-602 dbr:AK602
is foaf:primaryTopic of	wikipedia-en:Aplaviroc